Introduction
Stimulated by evidence of disease slowing with Teva/Lundbeck´s Azilect (rasagiline), and successful reformulation of leading dopamine agonists, the Parkinson´s disease market value is set to grow by an compound annual growth rate (CAGR) of 10% over the next 5 years (20072013), peaking at $3.1 billion in 2013.
Scope
*This report gives a strategic analysis of the likely impact that recent events will have on the future Parkinson´s disease market.
*Includes Parkinson´s disease-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017
*Provides a global market snapshot by including Parkinson´s disease-specific sales analysis for leading brands outside the seven major markets
*Key conclusions are supported by key opinion leader comment
Highlights
Datamonitor has upgraded its forecasts of Teva/Lundbeck´s Azilect (rasagiline) following clinical evidence of disease slowing. Over the next 5 years Azilect is expected to become a standard first-line therapy, with sales peaking in 2013, making it the leading market Parkinson´s disease drug at this time.
GlaxoSmithKline´s Requip XL (ropinirole extended-release) is set to become the market leading dopamine agonist in 2009. The convenience of once-daily dosing, supported by the theoretical clinical advantage of smoother dopamine receptor agonism, will drive switching from the parent compound and Boehringer Ingelheim´s Mirapex (pramipexole).
Datamonitor has downgraded its sales forecasts of UCB´s Neupro (rotigotine patch) as problems with crystallization of the active ingredient have led to supply issues at a critical phase in its lifecycle. Prescribers are now likely to switch to Requip XL, which arrived on the market at just the right time to take advantage of UCB´s misfortune.
Reasons to Purchase
*Understand the impact of recent and anticipated events on the Parkinson´s disease market during the forecast period 2008 to 2017
*Quantify the current size of the seven major markets and the trends in the rest of the world
*Assess the impact of events, such as patent expiries and new product launches, on the Parkinson´s disease-specific sales of key brands
Subscribe to:
Post Comments (Atom)
1 comment:
My husband was diagnosed with early onset Parkinson's disease at 57.his symptoms were shuffling of feet,slurred speech, low volume speech, degradation of hand writing, horrible driving skills, right arm held at 45 degree angle, things were tough for me, but now he finally free from the disease with the help of total cure ultimate health home, he now walks properly and all symptoms has reversed, he had trouble with balance especially at night, getting into the shower and exiting it is difficult,getting into bed is also another thing he finds impossible.we had to find a better solution for his condition which has really helped him a lot,the biggest helped we had was ultimatehealthhome they walked us through the proper steps,am highly recommended this ultimatehealthhome@gmail.com to anyone who needs help.
Post a Comment